Publicacións en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (7)

2017

  1. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer

    Oncotarget, Vol. 8, Núm. 9, pp. 15789-15801

2014

  1. NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

    Modern Pathology, Vol. 27, Núm. 10, pp. 1331-1337

  2. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases

    PLoS ONE, Vol. 9, Núm. 11

  3. PLCG1 mutations in cutaneous T-cell lymphomas

    Blood, Vol. 123, Núm. 13, pp. 2034-2043

2013

  1. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells

    Clinical Cancer Research, Vol. 19, Núm. 9, pp. 2319-2330

  2. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas

    Haematologica, Vol. 98, Núm. 1, pp. 57-64

2011

  1. HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines

    British Journal of Haematology